Alnylam Pharmaceuticals company profile
Company profile
Alnylam Pharmaceuticals has 2,500 employees and is headquartered in Cambridge, United States.
Alnylam's customers are patients with rare and chronic diseases in the United States, Europe and other international markets, where its RNA interference therapies are sold for conditions such as transthyretin amyloidosis, hypercholesterolemia, hemophilia and primary hyperoxaluria type 1. Its marketed medicines include ONPATTRO, AMVUTTRA, Leqvio, Qfitlia, GIVLAARI and OXLUMO, while its pipeline spans cardiovascular, metabolic, liver, neurological and hematological diseases, with several candidates in Phase 3 trials. The company develops, manufactures and commercializes these therapies and works with partners including Regeneron, Roche, Sanofi and Novartis.
In the fiscal year ended December 2025, Alnylam reported revenue of $3.7 billion, up 65.2% from the previous year, and net income of $313.7 million. The company had 2,500 employees and is headquartered in Cambridge, Massachusetts, where it was founded in 2002.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 675 West Kendall Street, 02142, Cambridge
- Employees
- 2,500
- Chief executive
- Yvonne Greenstreet
- Founded
- 2002
- Fiscal year
- January - December
- Listing
- ALNY · NASDAQ
- Indices
- Nasdaq 100
- Currency
- USD
- ISIN
- US02043Q1076
- Website
- alnylam.com
Alnylam Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Alnylam PharmaceuticalsALNY | United States | $22.11B | 2,500 | 19.5% | 8.34 |
| BioNTechBNTX | United States | $21.22B | 7,807 | -55.4% | — |
| IncyteINCY | United States | $24.36B | 2,844 | 32.2% | 61.0 |
| InsmedINSM | United States | $26.96B | 1,664 | -41.7% | — |
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
| Roivant SciencesROIV | United States | $28.64B | 721 | -3,226.3% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
